All right. Good afternoon, everyone. Welcome to Guggenheim's third annual Healthcare Innovation Conference. My name is Yatin Suneja, one of the biotech analysts here at the firm. It is my pleasure to introduce our next presenting company, Immunic. From the company, we have two executives here. We have Erik Lundgren, who is the Chief Executive Officer, and then we have Jason Tardio, who is the President and Chief Operating Officer. Erik, I am going to pass it on to you, maybe perhaps make some opening comments, tell us about what we should be focused on in the next, let's say, few months or so.
Yeah.
Then we will go into some of the Q&A that I have prepared for you.
Yeah, for sure. Thanks for having us, first of all. I think it is a really exciting time for us. We have two pivotal trials reading out in December, so we are right around the corner, right on the threshold of that data. These are two studies called ENSURE-1 and ENSURE-2, and they would, if they are positive, result in an NDA filing and approval in relapsing multiple sclerosis. So, I would say our priorities really are preparing for that readout, building the commercial launch apparatus and infrastructure to support it. Then we just announced last week, progressive MS study, a third pivotal trial in progressive MS called the ProTEct-MS study, that we are initiating right now, expecting the first patient in the first half of next year.
Got it. Maybe first question is on the corporate side and the commercial side. So you just joined recently, right, Erik? Then you have new CMO, there is a board chair. Jason, you have been here for a while. So, maybe just talk about how are you building from a corporate standpoint? How should we think about the commercial angle? Because if the data are positive, you could be filing NDA and you could be pretty close to commercial relatively soon. So, talk about those two components.
Yeah. I mean, I think I joined in June. I joined following 19 years at Genentech Roche. The reason I'm probably here is I was a part of launching ocrelizumab, which is the most prescribed MS medicine in the world today, and it was quite an experience to transform the MS market with the introduction of anti-CD20s. That was a decade ago, though, and I think I came because the unmet needs today are extremely clear in MS. They're as clear today as they were then, and I think the market is ripe for disruption again, and that's where I think this is allowing us to sort of lean in. As you said, I mean, I'm not the only new person. Our board, not only our board chair, multiple board members have turned over.
We've had the ability to bring in a bunch of executive and team level talents, which is really a reflection of this pivot from a development stage to a pre-commercial stage company. I'd say that's and then with the board changes, the remit strategically has also become crisper, which is about, this is an MS company focused on commercializing our lead asset.
Yeah.
That's where we are.
Jason, how about you?
Yeah. From a commercial perspective, we're actively preparing. Once we have successful data in December, it will be an accelerated effort to scale and ramp the company. We're not waiting for that. We've put a lot of work in place to validate our initial strategic assumptions around go-to-market strategy. We've begun to hire key leadership roles on the commercial side of the business, a VP of marketing. Today, we just had a new vice president of patient advocacy start at the company. We've built out the medical affairs organization and begun to deploy a series of medical science liaisons that are out there educating the market. We're doing a lot of work now, and of course, if we have successful data in December, we'll accelerate those efforts.
Got it. Very good. Very helpful. Let's just talk about the product or vidofludimus. What is the mechanism?
Sure.
I think one part of the mechanism, I think investors and even the physician community know, but it's the neuroprotective side of it, which is the Nurr1 activation.
Yeah.
It's not very well known. What do you get a sense, like how familiar are KOLs with this mechanism?
KOLs are quite excited about the Nurr1 activation side of our story. To sort of back up, though, vidofludimus calcium is a once-daily oral tablet, and it really has two underlying mechanisms, as you said, Yatin. There is DHODH inhibition, which is a proven pathway in relapsing MS, more on the neuroinflammatory side. But there is really nothing approved today that is neuroprotective.
Yeah.
That is where Nurr1 comes in. Nurr1 upregulates a series of genes that are associated with neuronal repair, resilience, and survival. If you understand the underlying disease mechanism in MS, there are sort of two underlying processes. One is sort of an autoimmune or neuroinflammatory disease component, hyperactive T and B cells, effectively. That is what everything approved in MS targets, either through modulation or suppression. Nothing is working on neurons directly, and nothing is really working in the CNS compartment directly. That is where the Nurr1 piece of vidofludimus calcium comes into play. So, if approved, we would be the only therapy that is working directly on neurons. The largest unmet need in MS today are medicines that create a meaningful impact on disability progression.
Yeah.
To do that effectively, you need to reach beyond relapse control and MRI control. You need to sort of get into that neuroprotective space. Vidofludimus calcium is a great shot on goal at that.
Got it. What sort of preclinical and clinical evidence you have produced to sort of prove this Nurr1 activation thesis?
Yeah. We have got a huge set of preclinical data. We shared some of it at the MS meeting in Toronto just a few weeks ago. We are very confident we are binding to activating Nurr1. We can see this in vivo and in vitro models. You can see neuronal survival against challenge. You can see that that effect goes away when you knock out Nurr1. We are very confident that this is a direct Nurr1 component as opposed to the DHODH piece of our mechanism. We have a quite robust set of preclinical findings. I think the piece that gets us most exciting is actually in the clinical findings. From our we had a phase II study in progressive MS, which was called the CALLIPER study. Relatively large phase II study, 467 patients.
While it was not powered for clinical outcomes, the clinical outcomes on progression, both in terms of slowing the worsening of the disease, but also patients improving on their disability, was very interesting and very compelling to us, especially in a patient population that had no evidence of neuroinflammatory disease-driving processes. This is the holy grail in MS drug development at the moment, is being able to move the needle in that hardest to treat population. We saw some very exciting, I would not say they are confirmatory of anything, it is phase II findings, nominal, all that stuff, but it gives us confidence going into a phase III study to prove it out.
Got it. With regard to the phase III studies that are going to read out relatively soon, can you maybe recap the design? How are they powered? What are the benchmark that we need to be paying attention to?
Yeah. They are kind of twin studies, the same exact protocol running on parallel tracks. They read out at the same time, ENSURE-1 and ENSURE-2. In total, we are talking about 2,221 patients, so massive studies, really large. 30 mg dose once daily of vidofludimus calcium versus placebo.
Yeah.
The primary endpoint is time to first relapse, so it is a relapse study. Then there is the normal slate of MRI and other relapse-related endpoints. Then we pool the studies to look at a bunch of progression-related endpoints.
Got it. How would you characterize like a win here? What would you need to show? Maybe if you want to recap the EMPhASIS-
EMPhASIS, yeah.
before we saw in the EMPhASIS.
EMPhASIS was our phase II study in relapsing disease, 260 some odd patients.
Seven.
67? Thank you. I mean, we haven't guided to a specific number for the ENSURE, but I would love to recapitulate what we saw in EMPhASIS. We saw a 42% risk reduction on relapse in that study, and we saw a very compelling safety and tolerability profile.
Yeah.
We haven't asked about that, but I mean, safety and tolerability really are essential components of treatment selection in MS. It's impossible to overstate how meaningful that is. It's a chronic disease. Neurologists are typically quite conservative. There are limitations on that side of the equation for everything that's approved today in MS. It's a huge area of white space for differentiation is on safety and tolerability.
Yeah. I'll come back to efficacy, but since you touched on the safety so we can address that, I mean, I think if you see the data across all the patient, it seems very benign from a safety standpoint. When you see the higher efficacy orals, they have either tolerability issues or let's say the BTKs. Maybe both of you can talk about profile that you expect, and then from a commercial standpoint, if BTKs come on the market, like how will the safety differentiation shake out?
Yeah. Let me start, and then I'll let Jason handle the differentiation. I think from a safety perspective, we have a pretty robust safety database, 3,500 odd patients. Some folks have been on for up to seven years. So we have a, for where we are in development, I'd say quite a robust read. I would also note that a placebo-controlled study is the highest bar you can possibly set on safety and tolerability. As you said, I joined the company in June. The first thing I looked at when I was doing my due diligence on the company was the safety and tolerability. I've seen everything in MS for the last dozen years or so, and I've never seen anything like this. It's quite impressive.
It takes care of a bunch of, or at least sort of knock on wood somewhere, thus far, we don't see any evidence of many of the either tolerability or serious safety issues that have plagued MS treatments. So, we see a very clean liver profile. We see a very, very clean infection profile. We don't see anything at all in terms of GI tox issues that are so prevalent with MS treatments today and lead to so much discontinuation of therapy. AUBAGIO or teriflunomide, which is also a DHODH inhibitor, but is sort of a first-generation version, has a bunch of off-target effects that are quite limiting, alopecia, embryo fetal tox, a bunch of things, some liver issues as well. All of those seem to have been cleaned up with the chemistry. I think that sets us up with, again, a highly differentiated profile.
Yeah, I think what I would add there is if you look across the oral disease-modifying therapy class, to Erik's point, there's benefit-risk trade-offs. What we think vidofludimus calcium may offer to the market is the best in oral class benefit-risk, and that's versus the currently marketed products and certainly versus any potential BTK inhibitor that may or may not make it to the market. I should remind you that it's a very sizable portion of the market. The oral class still makes up roughly 25%-30% of all prescriptions. It's a meaningful segment. It's a segment that's ripe for innovation, and we hope to deliver that with data in December.
Got it. Also, I think, Jason, maybe you and I had discussed it a while back. I think your product, vidofludimus, has a much shorter half-life versus teriflunomide. Can you talk about that dynamic? Is that something that physicians care about, the reversibility of the effect?
Certainly. Just to ground everyone here, the half-life of vidofludimus calcium is about 30 hours compared to upwards of 16 to 19 days, if you will, for teriflunomide. I mean, the serum half-life of these medicines is vastly different. Our medicine is out of the system within less than 10 days.
Yeah.
On teriflunomide, it can stay circulating in the bloodstream for over two years in some patients. As per their label, it mandates activated charcoal to rapidly eliminate that. When you think about the disease, a disease of young women, that's certainly a differentiator, and we think it's going to allow us to be possibly used in a population where teriflunomide has limitations.
Got it. All right, so now I want to go back on the safety side, at least in terms of the ENSURE-1 and 2 studies. A couple things. I think in October of 2024, there was an interim analysis, and then IDMC said, "Continue, no change." What is the implication or read-through, or how should we read that? I think you are doing a pooled analysis also of different endpoints, whether it's CDI or CDW. What should we be expecting there?
Yeah. On the interim question, I mean, I think that the IDMC was asked two questions. They unblinded the data and looked at it, and the questions were, "Is the study futile, yes or no?" No. The answer was no, it's not futile. The second was, "Are the powering assumptions that went into the study initially adequate to see a result, or should the sponsor change the protocol and add more power to the study?" The answer was, "Continue unchanged." That analysis was done at about half of the expected event rate, so about halfway through the study. What's the read-through? I think the read-through was they said continue. That's somewhat encouraging. Here we are today, sitting right on the cusp of the final answer. I don't think there's much more that you could say than that. It's encouraging.
I think that is a data point. I think the other data points I look to are the EMPhASIS study directly. The baseline demographics are very consistent between the phase II and the phase III enrolled population. The other piece, in relapsing MS in particular, gadolinium-enhancing lesions is an extraordinarily effective predictor in phase II of what your clinical outcomes in phase III are going to be when you look at meta-analyses. One of the nice things in MS is you have a lot of studies to do big meta-analyses on, and that has always been consistently the case. So if you see a gad lesion impact of 50% or more, you are pretty much in safe zone in terms of your primary outcome in the phase III. We had a 76% reduction in gad lesions, so we were well above that sort of general rule of thumb benchmark.
We feel that the phase III is largely de-risked on the primary outcome. Again, I will knock on wood just because I do not want to tempt the clinical trial gods too much.
Yeah. With regard to the pooled progression endpoint-
Yeah
what will be included? How would you define sort of success in these?
Yeah. We look at the because progression in relapsing studies are relatively rare events, you pool the studies together. We're not the only ones to do this. Pretty much every MS program does this in relapsing disease. They're hierarchically evaluated. We've done something a little bit novel with our stats plan, and we put an endpoint called net clinical benefit at the top. Net clinical benefit is still using the EDSS scale, which is the gold standard for how progression is followed and measured in MS patients. But it's using a general pairwise comparison, so it's basically getting more out of the same scale. Typically, you're going to look at disability, slowing disability progression is the kind of most standard endpoint utilized.
This does that as well, but it's also looking at and valuing if someone stays stable versus a person on the control arm that worsens, that's a win. If someone gets better versus someone that stays stable or gets worse, that's a win.
I see.
You get a lot more data out of it. This is a way of doing these analyses that's been used in oncology studies, and it's being explored in epilepsy studies. It's a way of using the gold standard tool, but to just get more signal out of it. That's our.
Got it. How would you characterize the phase II to phase III translation from an effect standpoint? I mean, would you expect any deterioration from what you show in EMPhASIS? That is one. The second is where we get more pushback from investors is that, look, you have these high-efficacy orals.
Maybe BTKs at some point will play in that mix. Why would somebody give up on the efficacy?
Well, on the read-through, I think you can look at the baseline characteristics, and I think the read-through is we have moved as few variables as you possibly can. I think I do not have much to add to that other than I think we have got a pretty clean read-through, we hope, and we would love to see it be in that zone. There is often a little drift off of a phase II to a phase III. It can actually drift in either direction, and I think we have plenty of room based on where we landed in the phase II, 42% risk reduction on relapses, which we think paired with our safety and tolerability profile, as Jason said, is a best-in-class total risk-benefit package. We can drift around that a little bit, and I think we are very viable commercially.
Got it. Maybe then go on the commercial side. Are there segments of patients that you would target? How large is the market?
Yeah.
How quickly you will be able to even file for an approval?
The way that we look at the market is, just as a reminder, the relapsing market in the U.S. is a large market, $17 billion today. It is going to grow to be a $25 billion market as we get into the 2030s. The other thing to remember is that there are 300,000 patients treated today with a disease-modifying therapy in relapsing MS. It is a dynamic market, which approximately 90,000 of those 300,000 are actively looking for something new on an annual basis. These are individuals coming in and initiating therapy. These are individuals that are switching therapies. It is not a zero-sum or a one-size-fits-all. The market itself, patients have this 30 or 40-year journey on a disease-modifying therapy.
What you really want is a medicine that is going to meet that patient at different points in their potential journey, whether that is when they are initiating therapy, whether it is when they are switching therapy, whether it is when they are older. The way that we look at the market is that, again, it only takes about a 4%-5% total market share capture to drive a billion dollars in sales. What we do is we look at the value proposition of vidofludimus calcium, a uniquely novel mechanistic approach to address both aspects of the disease, as we discussed, a selective inhibitor of DHODH for anti-inflammatory properties, an activator, the only medicine in development that activates Nurr1 for neuroprotective properties. We have driven great efficacy results to date balanced with what we think could be best in disease safety and tolerability.
That is a profile that we think is a winner. Again, you asked a little about high efficacy therapies, et cetera. Efficacy is certainly an important consideration, but it is not the only attribute that clinicians and patients will think about when they are making treatment selections. What they are looking at is the holistic picture. So what does efficacy look like compared to safety, compared to tolerability, compared to convenience? If you take all of these factors into place here, again, we believe vidofludimus calcium is going to offer a highly differentiated medicine, specifically within the oral class, and we think we have a commercial winner on our hands.
Got it.
I'd say the other big conversation in the MS community today is how long is too long to be on an anti-CD20? Anti-CD20s have become the dominant sort of mechanistic sort of class, right? Anywhere, it's about 50% of the market is on an anti-CD20 today. It's more than that in terms of treatment initiation of a treatment-naive patient, probably 70%, 75% of patients are going to start on an anti-CD20. But the thing is, as Jason said, people are going to live with managing their MS for 30 or 40 years. Pretty much all the doctors I talk to, there's not a consensus view, but it's somewhere around three years, between three years and eight years, depending on the doctor and probably depending on the patient across from them, where they're starting to say, "That's too much risk now.
There's too much risk for opportunistic infection or other issues." You're not going to be on an anti-CD20 forever. If you think about the market today, again, I was a part of launching OCREVUS 10 years ago. It was 10 years ago in March that that medicine launched. It's been the dominant medicine for the last six years. There's a lot of patients that have been on anti-CD20s continuously for a really long time, and there is not a therapy available today that makes sense as a switch to off of an anti-CD20, because most of the medicines today are either immunosuppressors or have infection risk or have tolerability issues that are going to limit patient acceptance, or have PML-associated risk, which is the big scary side effect in MS. That's where Vido, I think, is such a natural, easy fit right out of the gate.
Yeah.
It's a huge need. Every doctor you talk to that has more than a handful of patients in their clinic that they're treating for MS is going to talk about it. We see an immediate opportunity to slide in there.
Got it. How quickly you will be able to file, and would you want to launch it on your own in the U.S.? What about OUS?
Absolutely. We are planning to launch it on our own. You asked in the beginning about some of the board changes, and that is really what that was about, is about pivoting to being a commercial company and building ourselves. That is the remit of the board. That is the strategy of the management team. That is what we are building and planning to do. In terms of filing, middle of next year would be the goal for filing. Middle of 2028 is sort of the general guidance around launch.
Got it. I think last week you did an R&D day on the progressive MS side.
Yeah.
Perhaps would you like to recap, number one, the finding in CALLIPER and what the path forward did and the timelines around this phase III study?
Yeah. CALLIPER was our phase II study in progressive MS. As I said, some very exciting findings. I should note, the primary endpoint of that study was whole brain atrophy, and it missed on that, actually. Just to be very transparent about that. It has been subsequently shown in meta-analyses that whole brain atrophy is an incredibly poor predictor of the clinical outcomes. It is a little bit of a disappointment that the company had made that the primary endpoint. Nevertheless, there were a bunch of other findings in that study that were incredibly encouraging, both on the imaging side, so certain regions of the brain and volume changes, and then in particular on an endpoint called slowly expanding lesions, which is thought to be a real marker of this sort of smoldering progressive component of the disease, where we had a nominal statistical benefit on SELs.
But the clinical outcomes were what really caught my eye. In particular, in a subset of patient, a large group of the patients, about 85% of the patients who had no relapses and no gadolinium-enhancing lesions at baseline, so no evidence of any sort of inflammatory component happening with them, and we saw consistent directional benefit across worsening and improvement in those patients. If you are seeing that is something that has never really been shown before. This is a nominal finding in a phase II study, so it is not confirmatory of anything, but it does give us a lot of enthusiasm to charge into a phase III, which is what we announced last week. This is a study called the ProTEct-MS study, and it is going to be about 1,400 patients looking at a non-active progressive patient population.
Got it. What is the timeline for it?
We are initiating it now. First patient randomized first half of next year, and it will be about a three-year study.
Got it. Maybe then final question. How is the financial health of the company, the capital position?
Yeah, good. There was a big financing event that you are well aware of, but it was a big PIPE that was announced in February of this year. There is a second component of the PIPE that has the potential to convert warrants to cash and equity within 30 days of the public disclosure of the ENSURE-1 and 2 studies, so that is coming up. That would yield another $200 million of cash for us, which gives us runway into the back half of 2028.
Very good. Gentlemen, thank you so much.
Thank you so much.
Very good.
All right.
Thank you.
Thanks, sir.
Thank you. Thank you, Jason. Thank you.